E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Main objective of this clinical trial is to examine whether in patients with stable or unstable angina pectoris and / or documented myocardial ischemia in the presence of de-novo stenoses in native coronary arteries with a degree of stenosis between 50% and 99% an additional local administration of paclitaxel after implantation of a conventional stent is superior to the implantation of a conventional stent alone with respect to late lumen loss. In case of superiority it will be examined whether an additional local administration of paclitaxel after implantation of a conventional stent is not inferior to the implantation of a paclitaxel-eluting stent with respect to late lumen loss. Is this the case, superiority will be tested. |
|
E.2.2 | Secondary objectives of the trial |
1) A secondary objective of this clinical trial is the angiographical determination of the binary restenosis rate, defined as diameter stenosis of at least 50% in the stent and / or peristent area, 6 months after stent implantation. 2) A secondary objective of this clinical trial is the angiographical determination of the degree of stenosis, defined as percentage diameter stenosis in the stent and / or peristent area, 6 months after stent implantation. 3) A secondary objective of this clinical trial is the angiographical determination of the minimal lumen diameter in the stent and / or peristent area, 6 months after stent implantation. 4) A secondary objective of this clinical trial is the 6 months after stent implantation determined combined endpoint of abrupt and subabrupt closure of the target vessel, target lesion revascularisation and major adverse cardiac events including myocardial infarction and death.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age: 18-80 years, gender: male and female - Stable or unstable angina pectoris and / or documented myocardial ischemia - Ability and willingness to adhere to the study conditions - Written informed consent - De-novo stenosis of coronary artery with a degree of stenosis between 50% and 99%, that is accessible to PTCA - Target vesses diameter of at least 2,5 mm and length of lesion below 18 mm
|
|
E.4 | Principal exclusion criteria |
- Acute myocardial infarction or still elevated CK/CK-MB after acute myocardial infarction - Known severe arrhythmias that necessitate a long term antiarrhythmic therapy - Pericarditis - Intracardial thrombus - Bacterial endocarditis - Cardiopulmonary reanimation with cardiac massage within the last 6 months - Thromboembolic accident within the last 6 months - Severe peripheral arterial occlusive disease, that excludes the use of a 6 French catheter or that requires a special antithrombotic or anticoagulatory regime - Manifest hyperthyreosis - Neutrohile granulocytes less than 3000/mm3 and platelets below 100.000 or above 700.000/mm3 - Renal insufficiency with serum creatinine above 1,5 mg/L - Severe systemic hypertension despite antihypertensive medication - Other diseases which might lead to protocol violations or reduce life expectancy - Life expectancy below 1 year - Poor general condition - Premenopausal women, women who are postmeopausal less than 2 years - Known allergy or hypersensitivity to one of the components of TAXOL®, to one of the stent components, to ASS, clopidogrel, heparin or contrast agent - Concurrent participation or participation within the last 30 days prior to screening in another drug trial or a trial with a medical device - Bifurcation stenosis, ostium stenosis, main stem stenosis of the target vessel - Severly curved or sclerosed target vessel - Visible thrombus in target vessel - Complete closure of target vessel - Severe impairment of left ventricular function with left ventricular ejection fraction of less than 30% - Patients with expected indication for operative myocardial revascularisation within the next six months - Patients with contraindication for aortocoronary bypass operation - Patients who are principally not available for a second coronary angiography 6 months after stent implantation or who have a contraindication for a second coronary angiography
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary objective of this clinical trial is the angiographical determination of the late lumen loss in the stent and / or peristent area, 6 months after stent implantation.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
2 different medical devices |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is the last telephone interview of the last subject undergoing the trial which takes place at 3 years+/-60days post interventionem. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 12 |